Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NG004
- Development stage
- Phase 1
- Lead developer
- NovaGo Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NG004 is a recombinant human monoclonal antibody developed by NovaGo Therapeutics for the treatment of acute spinal cord injury. It targets and inhibits Nogo-A (also known as Reticulon-4 or RTN4), a protein that restricts nerve growth and regeneration in the central nervous system. By blocking Nogo-A, NG004 aims to promote nerve repair and functional recovery after spinal cord injury. Preclinical studies have also shown its potential to restore blood supply and retinal function in animal models of diabetic retinopathy by enabling normal vascular growth in the retina[1][2][3][5][6]. The drug is currently in Phase 1 clinical trials for acute spinal cord injury but development for diabetic retinopathy and stroke has been discontinued[2][3].
- Other names
- Anti-Nogo-A antibody
02
Targets
RTN4 (Reticulon-4)
Beyond the preview
Go deeper on NG004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NG004.